Results 1 to 10 of about 16,314 (147)

Impact of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors on Lipoprotein(a) [PDF]

JACC: Advances
Background: Lipoprotein(a) [Lp(a)] has been independently associated with increased cardiovascular risk. Objectives: The authors examined the effect of monoclonal antibody proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9is) on plasma Lp(a)
Frederick Berro Rivera, MD, Sung Whoy Cha, MD, Cruz Linnaeus Louisse, MD, Genquen Philip Carado, MD, John Vincent Magalong, MD, Vincent Anthony Tang, MD, Mary Grace Enriquez, MD, Martha Gulati, MD, MS, Byambaa Enkhmaa, MD, PhD, Neha Pagidipati, MD, MPH, Nishant P. Shah, MD   +10 more
doaj   +2 more sources

Natural phytochemicals as small-molecule proprotein convertase subtilisin/kexin type 9 inhibitors [PDF]

Tzu Chi Medical Journal
A decrease in the levels of low-density lipoprotein receptors (LDLRs) leads to the accumulation of LDL cholesterol (LDL-C) in the bloodstream, resulting in hypercholesterolemia and atherosclerotic cardiovascular diseases.
Je-Wen Liou, Pei-Yi Chen, Wan-Yun Gao, Jui-Hung Yen   +3 more
doaj   +2 more sources

Assessment of serum proprotein convertase subtilisin/kexin type 9 in pediatric sepsis syndrome [PDF]

Scientific Reports
Sepsis is a life-threatening condition that arises when the body's response to infection causes injury to its tissues and organs. Proprotein convertase subtilisin/kexin type 9 (PCSK9) is an enzyme released in response to the drop in cholesterol level ...
Suzan Omar Mousa, Mohamed Farouk Afifi, Noha Anwar Hassuna, Michael Fekry Yassa, Hend Mohamed Moness   +4 more
doaj   +2 more sources

A molecular modeling approach for structure-based virtual screening and identification of novel anti-hypercholesterolemic agents from Grape

Informatics in Medicine Unlocked, 2022
Hypercholesterolemia is a potential cardiovascular hazard that requires immediate therapeutic intervention. Research has shown that 3-Hydroxy-3-methylglutaryl- CoA reductase (HMG CoA reductase) and Proprotein convertase subtilisin/kexin type 9 (PCSK9 ...
Precious A. Akinnusi, Samuel O. Olubode, Adebowale A. Alade, Samad A. Ahmed, Susan F. Ayekolu, Taiwo M. Ogunlade, Damilola J. Gbore, Olayemi D. Rotimi, Abigail O. Ayodele   +8 more
doaj   +1 more source

Enteroendocrine Dysfunction in Two Saudi Sisters

Case Reports in Gastroenterology, 2021
Proprotein convertase (PC) deficiency is a rare autosomal recessive disorder caused by mutations in proprotein convertase subtilisin/kexin type 1 (PCSK1).
Amna Basheer M. Ahmed, Badr M. Rasheed Alsaleem   +1 more
doaj   +1 more source

Injection of an improperly stored proprotein convertase subtilisin/kexin type 9 monoclonal antibody in a patient with secondary dyslipidemia from nephrotic syndrome: a case report

Journal of Medical Case Reports, 2023
Background Elevated plasma cholesterol and/or plasma triglyceride levels in nephrotic syndrome patients are the result of impaired lipoprotein clearance and a compensatory increase in hepatic lipoprotein synthesis. Plasma proprotein convertase subtilisin/
Tanawan Kongmalai, Nalinee Chuanchaiyakul, Yuttana Srinoulprasert, Nuntakorn Thongtang   +3 more
doaj   +1 more source

Furin is the major proprotein convertase required for KISS1-to-Kisspeptin processing. [PDF]

PLoS ONE, 2014
KISS1 is a broadly functional secreted proprotein that is then processed into small peptides, termed kisspeptins (KP). Since sequence analysis showed cleavage at KR or RR dibasic sites of the nascent protein, it was hypothesized that enzyme(s) belonging ...
Sitaram Harihar, Keke M Pounds, Tomoo Iwakuma, Nabil G Seidah, Danny R Welch   +4 more
doaj   +1 more source

Cationic Cell-Penetrating Peptides Are Potent Furin Inhibitors. [PDF]

PLoS ONE, 2015
Cationic cell-penetrating peptides have been widely used to enhance the intracellular delivery of various types of cargoes, such as drugs and proteins.
Bruno Ramos-Molina, Adam N Lick, Amir Nasrolahi Shirazi, Donghoon Oh, Rakesh Tiwari, Naglaa Salem El-Sayed, Keykavous Parang, Iris Lindberg   +7 more
doaj   +1 more source

Sex difference in circulating PCSK9 and its clinical implications

Frontiers in Pharmacology, 2022
Proprotein convertase subtilisin kexin type 9 (PCSK9) is a proprotein convertase that increases plasma low-density lipoprotein cholesterol (LDL-C) levels by triggering the degradation of LDL receptors (LDLRs).
Fang Jia, Si-Fan Fei, De-Bing Tong, Cong Xue, Jian-Jun Li   +4 more
doaj   +1 more source

Hysteretic behavior of proprotein convertase 1/3 (PC1/3). [PDF]

PLoS ONE, 2011
The proprotein convertases (PCs) are calcium-dependent proteases responsible for processing precursor proteins into their active forms in eukariotes.
Marcelo Y Icimoto, Nilana M Barros, Juliana C Ferreira, Marcelo F Marcondes, Douglas Andrade, Mauricio F Machado, Maria A Juliano, Wagner A Júdice, Luiz Juliano, Vitor Oliveira   +9 more
doaj   +1 more source